Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
ArriVent BioPharma, Inc. - Common Stock
(NQ:
AVBP
)
23.92
-0.28 (-1.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ArriVent BioPharma, Inc. - Common Stock
AVBP Stock Earnings: ArriVent BioPharma Misses EPS for Q2 2024
August 14, 2024
AVBP stock results show that ArriVent BioPharma missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
June 08, 2024
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent...
Via
Talk Markets
AVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024
May 08, 2024
AVBP stock results show that ArriVent BioPharma beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
ArriVent BioPharma Reports First Quarter 2024 Financial Results
May 08, 2024
From
ArriVent BioPharma, Inc.
Via
GlobeNewswire
ArriVent Appoints Kristine Peterson to its Board of Directors
April 22, 2024
From
ArriVent BioPharma, Inc.
Via
GlobeNewswire
ProfoundBio Discovers The Joys Of Having A Wealthy Owner
April 08, 2024
Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a...
Via
Benzinga
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal
March 30, 2024
South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770 million. The company acquiring the asset asked to remain anonymous because...
Via
Talk Markets
$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying
February 02, 2024
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.
Via
Benzinga
KKR-Backed BrightSpring Prices Below Expectations, Then Opens Lower
January 28, 2024
Health-care services provider BrightSpring, which is backed by private equity firm KKR, priced its initial public offering at $13, below a marketed range of $15 to $18 per share, before opening on...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Week In Review: Arrivent BioPharma Raises $175 Million In IPO For In-Licensings From China
January 27, 2024
ArriVent BioPharma priced its upsized Nasdaq IPO at $18 dollars per share, raising $175 million. The company’s stated goal is to find promising novel assets from China and other countries, which it...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.